Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedAug 14, 2026
DataAggregated Company Financials
Companies65
  • 7D3.4%
  • 3M35.2%
  • 1Y20.3%
  • YTD3.9%

In the last week, the Life Sciences industry is up 3.4%, with Thermo Fisher Scientific up 2.7%. In the last 12 months, the industry was up 20%. As for the next few years, earnings are expected to grow by 19% per annum.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 14 Aug 2026US$709.2bUS$153.9bUS$14.1b37.9x50.3x4.6x
Sun, 12 Jul 2026US$650.5bUS$151.2bUS$13.6b45.3x47.7x4.3x
Tue, 09 Jun 2026US$586.3bUS$150.6bUS$13.8b38.4x42.6x3.9x
Thu, 07 May 2026US$555.7bUS$150.2bUS$14.0b33.7x39.7x3.7x
Sat, 04 Apr 2026US$561.8bUS$147.8bUS$14.1b37.2x39.9x3.8x
Mon, 02 Mar 2026US$599.3bUS$147.9bUS$14.0b35.2x42.9x4.1x
Wed, 28 Jan 2026US$696.9bUS$145.9bUS$12.4b35.8x56.3x4.8x
Fri, 26 Dec 2025US$664.7bUS$145.8bUS$12.5b35.3x53.3x4.6x
Sun, 23 Nov 2025US$666.0bUS$145.6bUS$12.4b36.2x53.8x4.6x
Tue, 21 Oct 2025US$636.0bUS$144.3bUS$14.6b32.5x43.7x4.4x
Thu, 18 Sep 2025US$571.0bUS$144.3bUS$14.6b29.7x39.2x4x
Sat, 16 Aug 2025US$580.5bUS$144.2bUS$14.5b29x40.1x4x
Mon, 14 Jul 2025US$551.9bUS$142.9bUS$9.1b36.9x60.5x3.9x
Wed, 11 Jun 2025US$525.9bUS$142.9bUS$9.2b36.7x57.4x3.7x
Fri, 09 May 2025US$511.1bUS$142.7bUS$9.6b35x53.2x3.6x
Sun, 06 Apr 2025US$509.0bUS$142.5bUS$9.9b33.4x51.2x3.6x
Tue, 04 Mar 2025US$605.1bUS$143.0bUS$9.7b37.7x62.4x4.2x
Thu, 30 Jan 2025US$705.6bUS$142.4bUS$10.2b41.1x69.1x5x
Sat, 28 Dec 2024US$659.4bUS$142.4bUS$10.2b44.7x64.5x4.6x
Mon, 25 Nov 2024US$656.8bUS$142.4bUS$10.4b44.1x63.4x4.6x
Wed, 23 Oct 2024US$727.8bUS$140.7bUS$8.2b36.7x88.7x5.2x
Fri, 20 Sep 2024US$744.1bUS$141.8bUS$8.5b38.1x87.6x5.2x
Sun, 18 Aug 2024US$738.6bUS$141.5bUS$8.4b38.8x88.3x5.2x
Tue, 16 Jul 2024US$685.9bUS$141.2bUS$12.2b41x56.2x4.9x
Thu, 13 Jun 2024US$706.7bUS$141.3bUS$12.2b37.6x58x5x
Sat, 11 May 2024US$719.0bUS$141.5bUS$12.7b38.6x56.8x5.1x
Mon, 08 Apr 2024US$727.9bUS$142.1bUS$12.8b43.1x56.9x5.1x
Wed, 06 Mar 2024US$747.1bUS$142.1bUS$12.8b44.3x58.2x5.3x
Fri, 02 Feb 2024US$710.9bUS$147.6bUS$12.5b38.7x56.8x4.8x
Sun, 31 Dec 2023US$700.9bUS$153.8bUS$14.2b37.8x49.2x4.6x
Tue, 28 Nov 2023US$642.9bUS$153.8bUS$14.0b34.5x45.9x4.2x
Thu, 26 Oct 2023US$578.1bUS$153.9bUS$10.8b29.9x53.6x3.8x
Sat, 23 Sep 2023US$670.2bUS$154.6bUS$11.2b31.2x59.8x4.3x
Mon, 21 Aug 2023US$702.8bUS$154.6bUS$11.2b32.5x62.7x4.5x
Price to Earnings Ratio

62.7x


Total Market Cap: US$702.8bTotal Earnings: US$11.2bTotal Revenue: US$154.6bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 55.7x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 50.3x which is lower than its 3-year average PE of 55.7x.
  • The industry is trading close to its 3-year average PS ratio of 4.4x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 7.9% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.74%
Healthcare2.29%
Life Sciences3.40%
Clinical Research and Equipment3.40%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$595.892.7%
+US$5.9b		22.9%PE31.6x
DHR DanaherUS$203.892.0%
+US$2.7b		-3.0%PE35.9x
A Agilent TechnologiesUS$149.295.6%
+US$2.2b		25.6%PE29.8x
TXG 10x GenomicsUS$58.1527.5%
+US$1.8b		339.2%PS12.3x
IQV IQVIA HoldingsUS$241.523.9%
+US$1.5b		27.5%PE28.9x

Latest News

WST
US$346.16
West Pharmaceutical Services
7D
-0.7%
1Y
40.6%
MEDP
US$581.95
Medpace Holdings
7D
-0.5%
1Y
26.9%
TMO
US$595.89
Thermo Fisher Scientific
7D
2.7%
1Y
22.9%
QTRX
US$2.86
Quanterix
7D
-25.3%
1Y
-37.0%
Analysis Article • 22h

Earnings Update: Quanterix Corporation (NASDAQ:QTRX) Just Reported And Analysts Are Trimming Their Forecasts

It's shaping up to be a tough period for Quanterix Corporation ( NASDAQ:QTRX ), which a week ago released some...
ABCL
US$10.97
AbCellera Biologics
7D
68.0%
1Y
143.8%
TXG
US$58.15
10x Genomics
7D
27.5%
1Y
339.2%
Analysis Article • Aug 12

US$49.54 - That's What Analysts Think 10x Genomics, Inc. (NASDAQ:TXG) Is Worth After These Results

A week ago, 10x Genomics, Inc. ( NASDAQ:TXG ) came out with a strong set of quarterly numbers that could potentially...
RPID
US$1.70
Rapid Micro Biosystems
7D
-18.3%
1Y
-39.7%
Analysis Article • Aug 12

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Just Reported Earnings, And Analysts Cut Their Target Price

It's been a sad week for Rapid Micro Biosystems, Inc. ( NASDAQ:RPID ), who've watched their investment drop 18% to...
DHR
US$203.89
Danaher
7D
2.0%
1Y
-3.0%
WAT
US$413.51
Waters
7D
3.5%
1Y
40.9%
ILMN
US$192.64
Illumina
7D
-0.6%
1Y
92.5%
Narrative Update • Aug 10

ILMN: Strong Clinical Sequencing Trends Will Likely Fail To Offset Execution Risks

Illumina's updated fair value estimate rises from $87.05 to $126.91 as analysts lift price targets across the sector, citing stronger Q2 results, solid instrument placements that may support consumables usage, and improving sentiment around clinical sequencing and long term growth initiatives. Analyst Commentary Recent research coverage on Illumina points to a clear reset higher in price targets across much of Wall Street.
IQV
US$241.52
IQVIA Holdings
7D
3.9%
1Y
27.5%
Narrative Update • Aug 10

IQV: Tech Differentiation And CRO Inflection Will Support Backlog And Margin Recovery

Analysts have lifted the fair value estimate for IQVIA Holdings to $300.00 from $270.37. They point to stronger bookings, a firmer clinical research environment, and confidence in the company's tech and data platform.
LAB
US$0.75
Standard BioTools
7D
-6.3%
1Y
-38.5%
Narrative Update • Aug 09

LAB: Pending Treeline Merger And Contingent Value Rights Will Support Future Upside

Analysts have trimmed their $1.55 price target on Standard BioTools to $1.35, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E that they view as better aligned with the company’s current risk and return profile. What’s in the News for Standard BioTools Treeline Biosciences agreed to acquire Standard BioTools in a reverse merger valued at about US$2.5b for Treeline and an estimated US$460 million for Standard BioTools, with the combined company expected to operate as Treeline Biosciences and trade on Nasdaq under the ticker TRLN once the deal closes.
MRVI
US$5.78
Maravai LifeSciences Holdings
7D
-7.5%
1Y
122.3%
TEM
US$54.29
Tempus AI
7D
17.7%
1Y
-24.2%
DNA
US$7.24
Ginkgo Bioworks Holdings
7D
-14.8%
1Y
-43.9%
A
US$149.29
Agilent Technologies
7D
5.6%
1Y
25.6%